Recombinant Human Tumor necrosis factor receptor superfamily member 6 (FAS)

What is the molecular structure of recombinant human FAS protein?

Recombinant human FAS protein consists of a 319 amino acid polypeptide with a single transmembrane domain. The extracellular domain is rich in cysteine residues and shows similarity to other members of the TNF receptor superfamily, including human tumor necrosis factor receptors, human nerve growth factor receptor, and human B cell antigen CD40. It typically exists as a membrane glycoprotein of approximately 48-kDa .

The protein contains specific structural features that facilitate its function in apoptotic signaling, including a death domain in the cytoplasmic region that is essential for downstream signaling. When working with recombinant versions, researchers should verify the presence of these critical domains to ensure biological functionality.

What expression systems are most effective for producing recombinant human FAS?

For producing recombinant human FAS proteins, several expression systems have been employed successfully. While the search results don't specifically detail FAS expression systems, similar TNF receptor family members like DR6/TNFRSF21 have been successfully expressed in insect cell systems such as Spodoptera frugiperda (Sf21) with baculovirus .

For FAS specifically, mammalian expression systems are often preferred when post-translational modifications are critical for function. The choice between prokaryotic and eukaryotic expression systems should be guided by:

• The intended use of the recombinant protein

• Required post-translational modifications

• The specific domain structure needed

• The scale of production required

Researchers should optimize culture conditions, including media composition, induction parameters, and harvesting timepoints to maximize yield and functionality.

How can researchers verify the functional activity of recombinant FAS proteins?

Functional verification of recombinant FAS proteins should involve multiple complementary approaches:

• Binding assays: Similar to approaches used for other TNFR superfamily members, binding activity can be assessed through ELISA-based methods. For example, when evaluating recombinant DR6/TNFRSF21, binding to its ligand APP770 is measured by coating the ligand at 2 μg/mL (100 μL/well) and determining the concentration of the recombinant protein that produces 50% of optimal binding .

• Apoptosis induction: Since FAS mediates apoptosis, functional activity can be determined by measuring its ability to induce programmed cell death in appropriate cell lines. This can be quantified using flow cytometry with Annexin V/PI staining, caspase activity assays, or other cell death markers.

• Receptor agonism assays: As demonstrated with Fas receptor agonist antibodies, the ability to trigger downstream signaling is a critical functional parameter . Signal transduction can be measured by assessing the activation of downstream caspases or other apoptotic markers.

What are the critical considerations when designing experiments with FAS receptor agonist antibodies?

When designing experiments with FAS receptor agonist antibodies, researchers should consider the non-intuitive relationship between antibody affinity and agonistic activity. As demonstrated in crystallography and protein engineering studies of anti-Fas antibodies, higher-affinity antibodies can surprisingly demonstrate reduced agonist activity at the Fas receptor .

Key experimental considerations include:

• Affinity optimization: Rather than assuming higher affinity translates to better agonism, researchers should test a range of antibody affinities and characterize their functional impact.

• Epitope selection: Crystal structure analysis at high resolution (e.g., 1.9 Å) can provide insights into epitope recognition and comparisons with the natural ligand FasL .

• Mechanism evaluation: When screening potential agonistic antibodies, assessing both binding parameters and functional outcomes is essential. Measuring apoptosis induction efficiency alongside binding kinetics will provide a more complete understanding of agonist properties.

• Comparison to natural ligand: Benchmarking antibody performance against the natural FAS ligand (FasL) allows for contextualization of experimental findings .

How can researchers address the receptor aggregation versus conformational change debate in FAS signaling?

The mechanism of FAS receptor activation, like many TNF receptor family members, remains under investigation with competing theories including receptor aggregation, conformational change, and segregation from intracellular inhibitors . Researchers can address this through:

• Structural biology approaches: X-ray crystallography, cryo-electron microscopy, and hydrogen-deuterium exchange mass spectrometry can capture different receptor states.

• Mutational analysis: Systematic mutation of residues involved in potential conformational changes or aggregation interfaces can help distinguish between these mechanisms.

• Live-cell imaging: Super-resolution microscopy techniques can visualize receptor clustering and conformational dynamics in real-time.

• Biochemical crosslinking: Chemical crosslinking followed by mass spectrometry can help identify the spatial relationships between receptors during signaling.

• Computational modeling: Molecular dynamics simulations can suggest potential mechanisms that can then be tested experimentally.

A comprehensive approach combining these methodologies will provide the most robust evidence for determining the dominant mechanism of FAS activation in different cellular contexts.

What strategies can overcome resistance to FAS-mediated apoptosis in experimental models?

Resistance to FAS-mediated apoptosis is a significant challenge in both experimental models and therapeutic applications. Several strategies can be employed to address this:

• Combination approaches: Combining FAS activation with inhibitors of anti-apoptotic proteins (like Bcl-2 family inhibitors) can enhance sensitivity.

• Targeting regulatory pathways: The TRAF6-NF-κB pathway has been implicated in regulating various TNF receptor signaling mechanisms . Modulating this pathway may influence FAS sensitivity.

• Epigenetic modifiers: Treatment with epigenetic drugs that can upregulate FAS expression or downregulate anti-apoptotic proteins may restore sensitivity.

• Alternative FAS agonists: When antibody-based approaches show limited efficacy, other modalities such as modified recombinant FasL or small molecule mimetics might overcome resistance.

• Cell-specific delivery: Targeted delivery of FAS agonists to specific cell populations can minimize off-target effects and potentially overcome resistance mechanisms.

Researchers should systematically characterize resistance mechanisms in their specific experimental system to select the most appropriate sensitization strategy.

What are the optimal storage and handling conditions for recombinant human FAS proteins?

Based on similar TNF receptor family proteins, recommended storage and handling conditions for recombinant human FAS include:

• Lyophilization format: Recombinant proteins are often lyophilized from a 0.2 μm filtered solution in PBS .

• Reconstitution protocol: Reconstitute at appropriate concentrations (typically 100 μg/mL) in sterile PBS .

• Storage temperature: Use a manual defrost freezer and avoid repeated freeze-thaw cycles to maintain protein integrity. Upon receipt, store immediately at the recommended temperature .

• Stability considerations: When carrier proteins (such as BSA) are not included (carrier-free preparations), special attention should be paid to protein stability, as adding carrier proteins typically enhances stability, increases shelf-life, and allows storage at more dilute concentrations .

• Working solution preparation: For experimental use, prepare working solutions fresh on the day of the experiment whenever possible.

A detailed record of freeze-thaw cycles and functional validation after extended storage is advisable to ensure experimental reproducibility.

How should researchers optimize ELISA-based detection methods for human FAS?

When optimizing ELISA-based detection methods for human FAS, consider the following parameters:

• Antibody selection: Using a combination of a monoclonal capture antibody (e.g., from mouse) and a biotinylated polyclonal detection antibody (e.g., from goat) can provide high specificity and sensitivity for FAS detection .

• Detection range: Establish a standard curve with appropriate range (e.g., 31.2pg/ml-2000pg/ml) to ensure accurate quantification .

• Sensitivity optimization: Aim for high sensitivity detection (e.g., <3pg/ml) through optimization of incubation times, temperatures, and detection systems .

• Cross-reactivity testing: Verify there is no detectable cross-reactivity with other relevant proteins that might be present in your experimental samples .

• Sample preparation: For different sample types (cell culture supernatants, serum, plasma), optimize specific pre-treatment protocols to minimize matrix effects.

• Validation using multiple approaches: Confirm ELISA results using orthogonal methods such as Western blotting or flow cytometry when establishing a new detection protocol.

What controls are essential when studying FAS-mediated apoptosis in cell culture systems?

When designing experiments to study FAS-mediated apoptosis, include these essential controls:

• Positive apoptosis controls: Include known apoptosis inducers (e.g., staurosporine) to validate that your detection system can effectively measure apoptotic events.

• Pathway specificity controls: Use specific inhibitors of the FAS pathway (such as caspase-8 inhibitors) to confirm the specificity of observed effects.

• Antibody specificity controls: When using agonistic antibodies, include isotype control antibodies to rule out non-specific effects .

• Cell type controls: Test FAS-expressing and FAS-negative cell lines in parallel to confirm receptor dependency.

• Concentration gradient: Perform dose-response studies with recombinant FAS or agonist antibodies to establish the relationship between receptor engagement and functional outcomes.

• Time course analysis: Monitor apoptosis at multiple time points to capture the dynamics of FAS-mediated cell death in your specific experimental system.

How can researchers address the affinity paradox observed with FAS receptor agonist antibodies?

The counterintuitive finding that higher-affinity antibodies can demonstrate reduced agonist activity at the FAS receptor presents a challenge for data interpretation. Researchers can address this paradox through:

• Kinetic analysis: Rather than focusing solely on equilibrium binding constants (KD), measure association and dissociation rates separately, as these may better predict functional outcomes.

• Epitope mapping: Determine precisely where different antibodies bind on the FAS receptor and correlate this with functional activity to identify optimal epitopes for agonism.

• Oligomerization assessment: Analyze the ability of different antibodies to induce receptor clustering, as this may be more predictive of agonistic activity than simple binding affinity.

• Structural studies: Use techniques like X-ray crystallography to understand how different antibodies engage with the receptor and potentially induce or inhibit conformational changes .

• Signaling pathway analysis: Assess downstream signaling events to determine whether higher-affinity binding might activate different pathways or inhibitory mechanisms.

Understanding this paradox may provide crucial insights for designing effective therapeutic agonists beyond the FAS system.

What approaches help resolve contradictory results between in vitro and in vivo FAS studies?

When faced with discrepancies between in vitro and in vivo FAS studies, consider these approaches:

• Microenvironmental factors: The tumor microenvironment contains cytokines that can sustain inflammation and stimulate tumor growth through pathways like NF-κB . Recreate these conditions in vitro by adding relevant cytokines or using co-culture systems.

• 3D culture systems: Bridge the gap between traditional 2D cultures and in vivo conditions using 3D culture systems, organoids, or ex vivo tissue slices that better maintain tissue architecture.

• Immune component consideration: FAS is expressed on activated human T and B lymphocytes , suggesting immune interactions may significantly influence outcomes. Consider immune-competent models and immune cell co-cultures.

• Pathway crosstalk: Investigate whether pathways like TRAF6-mediated signaling might influence FAS outcomes differently in complex in vivo environments compared to simplified in vitro systems.

• Physiological expression levels: Ensure that expression levels of FAS and related proteins in your experimental system match those observed in relevant tissues.

Comprehensive characterization of these factors can help explain apparent contradictions and lead to more predictive experimental models.

How can researchers distinguish between direct FAS-mediated effects and secondary consequences in complex biological systems?

Differentiating direct FAS-mediated effects from secondary consequences requires methodical experimental design:

• Temporal analysis: Map the chronological sequence of events following FAS activation to identify primary (rapid) versus secondary (delayed) responses.

• Genetic modification approaches: Use CRISPR-Cas9, siRNA, or dominant-negative mutants to selectively disrupt specific components of the FAS pathway and determine which outcomes are dependent on intact signaling.

• Pathway inhibitor panels: Apply selective inhibitors of various downstream pathways to determine which effects are mediated through canonical FAS signaling versus alternative pathways.

• Single-cell analysis: Heterogeneous responses within populations can confound interpretation. Single-cell techniques can reveal whether effects occur specifically in FAS-expressing cells.

• Ex vivo validation: Confirm key findings in freshly isolated primary tissues where the native architecture and signaling environment are preserved.

• Systems biology approaches: Integrate transcriptomic, proteomic, and metabolomic data to build comprehensive network models that distinguish direct signaling from downstream adaptive responses.

Through these approaches, researchers can build a more accurate picture of the direct consequences of FAS activation in their experimental system.